Search results
Showing 691 to 705 of 2208 results for guidelines
This guide describes the process NICE uses to develop NICE quality standards
Our forward view highlights the topics we will prioritise in the coming year.
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
Summary of the evidence on antimicrobial prescribing: delafloxacin
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)
Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
more about our updated maternal and child nutrition guideline We're joined by 2 members of the guideline committee, health...
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults